A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals
(Article)
Brugts, J.J. Isaacs, A. Remme, W.J. Bertrand, M.E. Ninomiya, T. Harrap, S. Chalmers, J. MacMahon, S. Fox, K. Ferrari, R. Simoons, M.L. Danser, A.H.J. Maat, M.P.M. de Boersma, E.R. Duijn, C.M. van Akkerhuis, K.M. Uitterlinden, A.G. Witteman, J.C.M. Cambien, F. Ceconi, C.
|
2011-03-01
|
Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease
(Article)
Brugts, J.J. Isaacs, A.J. MacMahon, S. Fox, K.M. Ferrari, R. Witteman, J.C.M. Danser, A.H.J. Simoons, M.L. Maat, M.P.M. de Boersma, E.R. Duijn, C.M. van Uitterlinden, A.G. Remme, W.J. Bertrand, M.E. Ninomiya, T. Ceconi, C. Chalmers, J.
|
2010-08-01
|
Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study
(Article)
Bertrand, M.E. Ferrari, R. Remme, W.J. Simoons, M.L. Deckers, J.W. Fox, K.M.
|
2010-05-01
|
The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: A combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials
(Article)
Brugts, J.J. Ninomiya, T. Boersma, H. Remme, W.J. Bertrand, M.E. Ferrari, R. Fox, K.M. MacMahon, S. Chalmers, J. Simoons, M.L.
|
2009-06-01
|
Secondary prevention of coronary disease with ACE inhibition-does blood pressure reduction with perindopril explain the benefits in EUROPA?
(Article)
Remme, W.J. Deckers, J.W. Fox, K.M. Ferrari, R. Bertrand, M.E. Simoons, M.L.
|
2009-04-01
|
The rationale and design of the perindopril genetic association study (PERGENE): A pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease
(Article)
Brugts, J.J. Maat, M.P.M. de Danser, A.H.J. Simoons, M.L. Boersma, H. Witteman, J.C.M. Duijn, C.M. van Uitterlinden, A.G. Bertrand, M.E. Remme, W.J. Fox, K.M. Ferrari, R.
|
2009-04-01
|
Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: A subgroup analysis of the EUROPA trial
(Article)
Bertrand, M.E. Fox, K.M. Remme, W.J. Ferrari, R. Simoons, M.L.
|
2009-02-01
|
ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: Results from the PERTINENT study
(Article)
Ceconi, C. Fox, K.M. Ferrari, R. Remme, W.J. Simoons, M.L. Deckers, J.W. Bertrand, M.E. Parrinello, G. Kluft, C. Blann, A. Cokkinos, D.V.
|
2008-01-01
|
The Cardioprotective Effects of the Angiotensin-Converting Enzyme Inhibitor Perindopril in Patients With Stable Coronary Artery Disease Are Not Modified by Mild to Moderate Renal Insufficiency. Insights From the EUROPA Trial
(Article)
Brugts, J.J. Boersma, H. Chonchol, M. Deckers, J.W. Bertrand, M.E. Remme, W.J. Ferrari, R. Fox, K.M. Simoons, M.L.
|
2007-11-27
|
Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: Data from the EUROPA trial
(Article)
Daly, C.A. Hildebrandt, P. Bertrand, M.E. Ferrari, R. Remme, W.J. Simoons, M.L. Fox, K.M.
|
2007-11-01
|